# OnCo record paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018" ;
  schema:name "Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma"@en ;
  schema:description "Phase 2 or 3 results paper on Brentuximab vedotin in Hodgkin lymphoma, in Blood (2018), one of the most cited Europe PMC records with Brentuximab vedotin in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1182/blood-2017-10-811224>, <https://pubmed.ncbi.nlm.nih.gov/29229594/>, <https://europepmc.org/article/MED/29229594> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1182/blood-2017-10-811224> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Herrera AF, Moskowitz AJ, Bartlett NL, et al." ;
  onco:journals <https://onco.cc/journals/blood/> .